ClinicalTrials.gg
CompletedNCT07036900Updated Nov 3, 2026

Effects of Flexion and Extension Type Arm Slings on Walking Kinematics and Balance in Stroke Patients

An observational study in Stroke, sponsored by Istanbul University - Cerrahpasa. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Istanbul University - Cerrahpasa · Observational

How we know

Updated Nov 3, 2026Now CompletedStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Stroke by Istanbul University - Cerrahpasa — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Istanbul University - Cerrahpasa.

Started
2024
with 2 others
Observational
4 of 22
none open now
Registered
19th of 22
by date

Among the 22 studies in Stroke by Istanbul University - Cerrahpasa, this one is one of 3 that started in 2024, is one of 4 observational ones, and was the 19th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 22 studies in Stroke by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stroke by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

In the clinic, stroke patients are seen to use flexor or extensor type arm slings, but no study was found investigating the effects of these different types of arm slings on walking kinematics and balance. The aim of the presented study was to investigate the effects of different types of arm slings on walking kinematics and balance in stroke patients and to compare them with healthy individuals.

Read the detailed description

Stroke is one of the most common diseases in the world, affecting one in every four people (Campbell \& Khatri, 2020). After stroke, approximately 80% of patients experience walking disorders (Algurén et al., 2010). Stroke survivors demonstrate gait disturbances such as reduced walking speed, step length and cadence (Balaban \& Tok, 2014). Deterioration in walking kinematics negatively affects daily living activities, confidence, self-care, social roles, family life and reducing quality of life in stroke survivors (Park \& Kim, 2019). Additionally, walking disturbances in stoke patients can lead to increased energy expenditure, pain and risk of falling (Balaban \& Tok, 2014; Shin et al., 2020). Besides, balance impairments are frequent clinical symptom in stroke survivors. Compared to healthy individuals, stroke patients have lower balance and walking capacity. Accordingly, the risk of falling increases, physical activity and participation reduces in individuals with stroke (Roelofs et al., 2023). Therefore, it is important that walking kinematics and balance in stroke survivors should have similar characteristics to the healthy individuals.

One of the frequently complications after stroke is shoulder subluxations. Shoulder subluxation increases the distance between the acromion and the humeral head, thus delay improvement of upper extremity motor function and decrease proprioception in stroke survivors (Paci et al., 2005). Electrical stimulation, robot-assisted upper extremity rehabilitation and arm slings are the physiotherapy and rehabilitation applications used to prevent shoulder subluxations in stroke patients (Jung \& Choi, 2019; Paci et al., 2005). Arm slings are often used to help reposition the humeral head in the glenoid fossa by counteracting gravity on the affected side (Jeong et al., 2022). In addition, it has been stated that arm slings have a positive effect on balance, increase walking efficiency, reduce spasticity and are a painless application in stroke survivors (Acar \& Karatas, 2010; Jeong et al., 2022). In the clinic, it has been observed that stroke patients use flexor or extensor type arm slings. However, no study has been found investigating the effects of these different types of arm slings on walking kinematics and balance in stroke patients. The aim of the presented study is to investigate different types of arm slings on walking kinematics and balance in stroke patients and compare with the healthy individuals.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Arm Slings
  • Walking Kinematics
  • Balance
  • Stroke
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This prospective, randomized controlled study involved ambulatory stroke patients (experimental group (EG)) and healthy individuals (control group (CG)).

Eligibility criteria

Inclusion Criteria:

  • Stroke diagnosis,
  • Age 18-80,
  • Independent ambulation (Functional Ambulation Category-FAS ≥ 2),
  • Modified Ashworth Scale-MAS ≤2 for gastrocnemius and biceps muscles,
  • Ability to walk 10 m independently or with assistive device, (6) physician approval for an exercise program.

Inclusion criteria for Control Group:

  • Healthy individuals without any additional neurological or orthopaedic diseases that may affect balance and gait,
  • Age 18-80
  • Physician approval for an exercise program.

Exclusion Criteria:

  • Severe visual impairments,
  • Cerebellar involvement
  • Upper extremity Brunnstrom stage ≤ 3,
  • Cancer diagnosis
  • Presence of a neurological or orthopedic condition other than stroke,
  • Inability to understand and follow commands or lack of cooperation
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Stroke patients (experimental group (EG))

    All test assesments were explained to the patient both verbally and visually. All assesments were applied for patients and healthy participants on the same day. Patients using assistive devices were assessed with these devices. Participants were initially assessed for gait analysis without an arm sling. Then, assessments were conducted by applying a flexor arm sling first, followed by an extensor arm sling. The assessments and data collection were conducted by physiotherapists.

    Other: No Interventions

  • Healthy individuals (control group (CG))

    All test assesments were explained to the patient both verbally and visually. All assesments were applied for patients and healthy participants on the same day. Patients using assistive devices were assessed with these devices. Participants were initially assessed for gait analysis without an arm sling. Then, assessments were conducted by applying a flexor arm sling first, followed by an extensor arm sling. The assessments and data collection were conducted by physiotherapists.

    Other: No Interventions

Interventions

  • OtherNo Interventions

    There is no treatment to be administered within the scope of this study.

06

What researchers measure

Primary outcomes

  1. PABLO ® Lower Extremity inertial sensor

    Inertial measurement unit (IMU) systems have been validated for measuring joint angles and temporal characteristics during lower extremity movements (O'Reilly et al., 2018). Gait parameters, such as stance and swing phase durations, step length, walking speed, and cadence, can be determined using two inertial sensors placed in the shoes. Each shoe is equipped with a PABLO Lower Extremity Inertial Sensor. The sensors measure angular velocity and acceleration at a sampling frequency of 110Hz. Each sensor transmits data via Bluetooth. The sensors are attached to the participants' shoes using custom Velcro straps. It has been found that inertial measurement unit systems work reliably not only in healthy individuals but also in patients, providing accurate results under different pathological gait patterns (Laidig et al., 2021). In our study, gait analysis was conducted to establish reference values by evaluating stroke patients and healthy individuals of the same age.

    Time frame: 8 minutes (approximately)

  2. TYMO ® Balance Plate

    The TYMO® Balance Plate (Tyromotion, Austria) is a standardized balance analysis device used to assess posture and balance in an upright stance. The TYMO® force sensors detect weight shifting and measure the center of pressure, body sway, and load balance on the feet. These data provide indicators of balance, stability, and symmetry. The TYMO® system is a versatile and easy-to-use assessment and treatment tool consisting of the TYMO Therapy Board and software. Participants are required to stand on a platform for 30 seconds and undergo four test positions: 1) feet apart, eyes open, firm support surface; 2) feet apart, eyes closed, firm support surface; 3) feet apart, eyes open, soft support surface/foam; 4) feet apart, eyes closed, soft support surface/foam. Each position was tested once, and the displacement of the center of body mass was measured in centimeters (Dudoniene et al., 2023).

    Time frame: 8-10 minutes (approximately)

Secondary outcomes

  1. Timed Up and Go Test

    The Timed Up and Go test is used to assess a person's walking speed, fall risk, and mobility (Wall et al., 2000). In this test, the patient is instructed to stand up from a chair, walk a previously marked 3-meter distance, turn, and then return to sit back down in the chair. The average time in seconds is recorded after three repetitions to find the result. A completion time longer than 13.5 seconds is considered indicative of an increased fall risk, while a time exceeding 20 seconds is associated with decreased mobility (Podsiadlo \& Richardson, 1991).

    Time frame: 3-5 minutes (approximately)

07

Study locations

1 site
  • Bahçeşehir Liv Hospital Neur-on
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — It is planned that patient data will not be shared with anyone.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jan 2025, 1 month.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's 1 month is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start May 2025 → Dec 2024, primary completion Dec 2025 → Jan 2025 and completion Apr 2026 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Dec 30, 2024was May 2025
Primary completionActual
Jan 30, 2025was Dec 2025
CompletionActual
Jan 30, 2025was Apr 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Start date
May 30, 2025→Dec 30, 2024
Nov 3, 2026
Primary completion
Dec 30, 2025→Jan 30, 2025 (actual)
Nov 3, 2026
Study completion
Apr 30, 2026→Jan 30, 2025 (actual)
Nov 3, 2026
Enrollment
48 (estimated)→20 (actual)
Nov 3, 2026
Eligibility
1 inclusion criterion removed; 1 exclusion criterion removed; 1 criterion edited, 16 added
What changed in the criteria
  • AddedInclusion Criteria:
  • AddedStroke diagnosis,
  • AddedAge 18-80,
  • AddedIndependent ambulation (Functional Ambulation Category-FAS ≥ 2),
  • AddedModified Ashworth Scale-MAS ≤2 for gastrocnemius and biceps muscles,
  • AddedAbility to walk 10 m independently or with assistive device, (6) physician approval for an exercise program.
  • AddedInclusion criteria for Control Group:
  • EditedInclusion criteria for CG: (1) healthyHealthy individuals without any additional neurological or orthopaedic diseases that may affect balance and gait, (2) age 18-80, (3) physician approval for an exercise program.
  • AddedAge 18-80
  • AddedPhysician approval for an exercise program.
  • AddedExclusion Criteria:
  • AddedSevere visual impairments,
  • AddedCerebellar involvement
  • AddedUpper extremity Brunnstrom stage ≤ 3,
  • AddedCancer diagnosis
  • AddedPresence of a neurological or orthopedic condition other than stroke,
  • AddedInability to understand and follow commands or lack of cooperation
Inclusion criteria
  • RemovedInclusion criteria for EG were: (1) stroke diagnosis, (2) age 18-80, (3) independent ambulation (Functional Ambulation Category-FAS ≥ 2), (4) Modified Ashworth Scale-MAS ≤2 for gastrocnemius and biceps muscles, (5) ability to walk 10 m independently or with assistive device, (6) physician approval for an exercise program.
Exclusion criteria
  • Removed(1) severe visual impairments, (2) cerebellar involvement, (3) upper extremity Brunnstrom stage ≤ 3, (4) cancer diagnosis, (5) presence of a neurological or orthopedic condition other than stroke, (6) inability to understand and follow commands or lack of cooperation.
Nov 3, 2026
Interventions
Arms or interventions changed
Nov 3, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time framePABLO ® Lower Extremity inertial sensor8 min. → 8 minutes (approximately)
  • Time frameTYMO ® Balance Plate8-10 min. → 8-10 minutes (approximately)
Nov 3, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameTimed Up and Go Test3-5 min. → 3-5 minutes (approximately)
Nov 3, 2026
Sponsor
Ceren Bayrak→Istanbul University - Cerrahpasa
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Completed
    Start date May 30, 2025→Dec 30, 2024
    Primary completion Dec 30, 2025→Jan 30, 2025 (now actual)
    Study completion Apr 30, 2026→Jan 30, 2025 (now actual)
    Enrollment 48 (estimated)→20 (actual)
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion removed; 1 criterion edited, 16 added
    What changed in the criteria
    • AddedInclusion Criteria:
    • AddedStroke diagnosis,
    • AddedAge 18-80,
    • AddedIndependent ambulation (Functional Ambulation Category-FAS ≥ 2),
    • AddedModified Ashworth Scale-MAS ≤2 for gastrocnemius and biceps muscles,
    • AddedAbility to walk 10 m independently or with assistive device, (6) physician approval for an exercise program.
    • AddedInclusion criteria for Control Group:
    • EditedInclusion criteria for CG: (1) healthyHealthy individuals without any additional neurological or orthopaedic diseases that may affect balance and gait, (2) age 18-80, (3) physician approval for an exercise program.
    • AddedAge 18-80
    • AddedPhysician approval for an exercise program.
    • AddedExclusion Criteria:
    • AddedSevere visual impairments,
    • AddedCerebellar involvement
    • AddedUpper extremity Brunnstrom stage ≤ 3,
    • AddedCancer diagnosis
    • AddedPresence of a neurological or orthopedic condition other than stroke,
    • AddedInability to understand and follow commands or lack of cooperation
    Inclusion criteria
    • RemovedInclusion criteria for EG were: (1) stroke diagnosis, (2) age 18-80, (3) independent ambulation (Functional Ambulation Category-FAS ≥ 2), (4) Modified Ashworth Scale-MAS ≤2 for gastrocnemius and biceps muscles, (5) ability to walk 10 m independently or with assistive device, (6) physician approval for an exercise program.
    Exclusion criteria
    • Removed(1) severe visual impairments, (2) cerebellar involvement, (3) upper extremity Brunnstrom stage ≤ 3, (4) cancer diagnosis, (5) presence of a neurological or orthopedic condition other than stroke, (6) inability to understand and follow commands or lack of cooperation.
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time framePABLO ® Lower Extremity inertial sensor8 min. → 8 minutes (approximately)
    • Time frameTYMO ® Balance Plate8-10 min. → 8-10 minutes (approximately)
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameTimed Up and Go Test3-5 min. → 3-5 minutes (approximately)
    Interventions Arms or interventions changed
    Sponsor Ceren Bayrak→Istanbul University - Cerrahpasa
    + 4 other changes: verification date, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07036900
Responsible party
Ceren Bayrak (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jun 25, 2025
Start date
Dec 30, 2024
Primary completion
Jan 30, 2025
Completion
Jan 30, 2025
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion